ABBV vs TMO: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Thermo Fisher Scientific Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
AbbVie Inc. · Healthcare
$197.69
+11.0% upside to fair value
Grade C
High Quality
VS
Thermo Fisher Scientific Inc. · Healthcare
$462.60
+10.1% upside to fair value
Grade B
QuantHub Verdict
ABBV has more upside to fair value
(+11.0%).
TMO trades at a lower forward P/E
(25.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
TMO |
| Current Price |
$197.69 |
$462.60 |
| Fair Value Estimate |
$219.51 |
$509.20 |
| Upside to Fair Value |
+11.0%
|
+10.1%
|
| Market Cap |
$349.7B |
$171.9B |
| Forward P/E |
83.3x
|
25.1x
|
| EV / EBITDA |
23.4x
|
19.0x
|
| Price / Sales |
5.7x
|
3.8x
|
| Price / FCF |
18.7x
|
25.5x
|
| Revenue Growth YoY |
+10.0%
|
+6.2%
|
| Gross Margin |
70.2%
|
39.4%
|
| Operating Margin |
26.7%
|
17.8%
|
| Return on Equity |
-361.6%
|
13.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
3.92%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Thermo Fisher Scientific Inc. operates in the healthcare sector, specializing in medical diagnostics and research tools across four main segments: Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics. The company demonstrates medium business quality with steady revenue growth of 6.2% and earnings growth of 9.6% in the most recent q…
Accumulation Zones
| Metric |
ABBV |
TMO |
| Zone Low |
$164.63 |
$381.90 |
| Zone High |
$186.58 |
$432.82 |
| In Buy Zone? |
No
|
No
|